“When you patrol the micro-cap market niche you will every so often feel a thrill if you think you have found a fabulous winner early,” said Bob Flaherty, financial news editor, in his recent newsletter, recommending PuraMed BioScience, Inc.®, as a company with a solid product offering and a bright future.
“It’s an honor to write about an unknown quality team trying to help 50 million Americans suffering from migraine headaches especially our suffering children. We believe investors can achieve double our usual target gains of 50% to 100% over two years,” said Flaherty.
Click here to read the entire article.
Related posts:
